The patient’s poor response to Osimertinib and Almonertinib initially, followed by a significant clinical improvement upon initiation of Olaparib monotherapy, suggests that the somatic BRCA2 mutation may have acted as a co-driver alongside EGFR, contributing to tumor progression and resistance to EGFR-TKIs. This evidence concerns the gene BRCA2 and neoplasm.